142 related articles for article (PubMed ID: 18374395)
61. The effectiveness of tamsulosin in treating women with voiding difficulty.
Chang SJ; Chiang IN; Yu HJ
Int J Urol; 2008 Oct; 15(11):981-5. PubMed ID: 18721208
[TBL] [Abstract][Full Text] [Related]
62. Comparison of HoLEP and TURP in terms of efficacy in the early postoperative period and perioperative morbidity.
Mavuduru RM; Mandal AK; Singh SK; Acharya N; Agarwal M; Garg S; Kumar S
Urol Int; 2009; 82(2):130-5. PubMed ID: 19321996
[TBL] [Abstract][Full Text] [Related]
63. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
[TBL] [Abstract][Full Text] [Related]
64. Hourglass-shaped nitinol prostatic stent in treatment of patients with lower urinary tract symptoms due to bladder outlet obstruction.
van Dijk MM; Mochtar CA; Wijkstra H; Laguna MP; de la Rosette JJ
Urology; 2005 Oct; 66(4):845-9. PubMed ID: 16230150
[TBL] [Abstract][Full Text] [Related]
65. Epithelializing stent for benign prostatic hyperplasia: a systematic review of the literature.
Armitage JN; Cathcart PJ; Rashidian A; De Nigris E; Emberton M; van der Meulen JH
J Urol; 2007 May; 177(5):1619-24. PubMed ID: 17437773
[TBL] [Abstract][Full Text] [Related]
66. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
67. Comparison of potassium-titanyl-phosphate laser vaporization of the prostate and transurethral resection of the prostate: update of a prospective non-randomized two-centre study.
Ruszat R; Wyler SF; Seitz M; Lehmann K; Abe C; Bonkat G; Reich O; Gasser TC; Bachmann A
BJU Int; 2008 Nov; 102(10):1432-8; discussion 1438-9. PubMed ID: 18671785
[TBL] [Abstract][Full Text] [Related]
68. [Effectiveness and safety of naftopidil for benign prostatic hyperplasia patients with overactive bladder symptoms].
Ge JP; Gong J; Ma HQ; Wei W; Shang XJ; Zhang ZY; Xu S; Wang D; Gao JP
Zhonghua Nan Ke Xue; 2008 Oct; 14(10):927-30. PubMed ID: 19157107
[TBL] [Abstract][Full Text] [Related]
69. Effect of ureteral stent diameter on ureteral stent-related symptoms.
Taguchi M; Yoshida K; Sugi M; Kinoshita H; Matsuda T
Low Urin Tract Symptoms; 2019 Sep; 11(4):195-199. PubMed ID: 30957387
[TBL] [Abstract][Full Text] [Related]
70. Experience with the spanner prostatic stent in patients unfit for surgery: an observational study.
Grimsley SJ; Khan MH; Lennox E; Paterson PH
J Endourol; 2007 Sep; 21(9):1093-6. PubMed ID: 17941793
[TBL] [Abstract][Full Text] [Related]
71. Bipolar transurethral resection in saline system versus traditional monopolar resection system in treating large-volume benign prostatic hyperplasia.
Chen Q; Zhang L; Liu YJ; Lu JD; Wang GM
Urol Int; 2009; 83(1):55-9. PubMed ID: 19641360
[TBL] [Abstract][Full Text] [Related]
72. Treatment options for benign prostatic hyperplasia in older men.
Miano R; De Nunzio C; Asimakopoulos AD; Germani S; Tubaro A
Med Sci Monit; 2008 Jul; 14(7):RA94-102. PubMed ID: 18591930
[TBL] [Abstract][Full Text] [Related]
73. Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: a pilot study.
Kravchick S; Cytron S; Mamonov A; Peled R; Linov L
Urology; 2009 Jun; 73(6):1274-8. PubMed ID: 19375786
[TBL] [Abstract][Full Text] [Related]
74. Clinical efficacy of naftopidil on lower urinary tract symptoms after radical prostatectomy.
Ishizaka K; Machida T; Tanaka M; Kawamura N; Nakamura K; Kihara K
Int J Urol; 2009 Mar; 16(3):299-302. PubMed ID: 19207610
[TBL] [Abstract][Full Text] [Related]
75. Relationship between lower urinary tract symptoms and metabolic syndrome in a community-based elderly population.
Park HK; Lee HW; Lee KS; Byun SS; Jeong SJ; Hong SK; Lee SE; Park JH; Lee SB; Kim KW;
Urology; 2008 Sep; 72(3):556-60. PubMed ID: 18597823
[TBL] [Abstract][Full Text] [Related]
76. [Fushile: a safe and effective therapeutic for benign prostatic hyperplasia].
Shang XJ; Liu ZY; Liu ZF; Sun YH; Huang YF
Zhonghua Nan Ke Xue; 2008 Mar; 14(3):227-30. PubMed ID: 18488335
[TBL] [Abstract][Full Text] [Related]
77. Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment.
Awa Y; Suzuki H; Hamano S; Okano T; Sakurayama Y; Ohki T; Egoshi K; Ota S; Mori I; Ichikawa T
Int J Urol; 2008 Aug; 15(8):709-15. PubMed ID: 18662175
[TBL] [Abstract][Full Text] [Related]
78. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
79. [Clinical analysis and management of disappointing early urination after TURP].
Wang YC; Lu Y; Song YS
Zhonghua Nan Ke Xue; 2009 Jan; 15(1):48-50. PubMed ID: 19288750
[TBL] [Abstract][Full Text] [Related]
80. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J;
BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
